Collaborations, New Contract, Dividend Declaration, and Capacity Expansion - Research Reports on Abbott, CB&I, Weyerhaeuser, Cardinal Health and SolarCity

NEW YORK, August 26, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Chicago Bridge & Iron Company N.V. (NYSE: CBI), Weyerhaeuser Co. (NYSE: WY), Cardinal Health, Inc. (NYSE: CAH) and SolarCity Corporation (NASDAQ: SCTY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5978-100free.

Abbott Laboratories Research Reports
On August 18, 2014, Abbott Laboratories (Abbott) and the United States Department of Defense announced a collaboration to develop portable blood tests that will help physicians accurately diagnose the potential concussions, also called mild traumatic brain injuries (TBIs), and prevent further injury. According to the Company, concussions are a significant health concern for military service members. Abbott stated that as part of a multi-phased approach, the tests would be developed for Abbott's i-STAT® System, a handheld, diagnostic analyzer that is currently used for other point-of-care testing, including among military service members. "Medical advances are needed to help more quickly assess concussions. The collaboration between Abbott and the Department of Defense is an important step in ensuring that military service members, and ultimately civilians, receive proper evaluation," said Beth McQuiston, M.D., a Board Certified Neurologist and Medical Director, Diagnostics, Abbott. "These new tests could open the door to many possibilities for evaluating concussions and helping clinicians optimize care and outcomes." The full research reports on Abbott are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/ABT/report.pdf

Chicago Bridge & Iron Company N.V. Research Reports
On August 21, 2014, Chicago Bridge & Iron Company N.V. (CB&I) announced that it has received a contract from Polski Koncern Naftowy Orlen S.A. (PKN) for the license and engineering design of a new on-purpose propylene production unit to be located in Plock, Poland. CB&I informed that it will deploy its proprietary Olefins Conversion Technology (OCT) at the proposed unit to produce 100,000 metric tons per annum (MTA) of propylene to be used internally. "As evidenced by this latest technology award, when producers want to make additional polymer grade propylene, they use CB&I's broad range of propylene producing technologies such as the Olefins Conversion Technology," said Daniel McCarthy, President of CB&I's Technology operating group. The full research reports on CB&I are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/CBI/report.pdf

Weyerhaeuser Co. Research Reports
On August 13, 2014, Weyerhaeuser Co. (Weyerhaeuser) announced that its Board of Directors has declared a dividend of $0.29 per common share, up from the previous quarterly dividend of $0.22 per share. Weyerhaeuser said with the stated increase it has grown its dividend by 93% since 2011. The Company said that the dividend is payable in cash on September 12, 2014, to holders of record of such common shares at the close of business on August 29, 2014. The Board also declared a dividend of $0.7969 per share on the Company's 6.375% Mandatory Convertible Preference Shares, Series A, payable October 1, 2014, to holders of record as of the close of business on September 15, 2014. In addition, the Board also authorized a new share repurchase program of up to $700 million of the Company's common shares. Weyerhaeuser informed that this new program will replace the prior share repurchase program. "This significant increase to our quarterly dividend coupled with our share repurchase program reflects our confidence in the company's ability to continue to improve operating and financial performance and is further evidence of Weyerhaeuser's ongoing commitment to return cash to our shareholders," said Doyle R. Simons, President and CEO. The full research reports on Weyerhaeuser are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/WY/report.pdf

Cardinal Health, Inc. Research Reports
On August 6, 2014, Cardinal Health, Inc. (Cardinal Health) announced that its Board of Directors approved a cash dividend of $0.3425 per common share payable on October 15, 2014, to shareholders of record at the close of business on October 1, 2014. The Board also authorized an increase of $1 billion to the Company's existing share repurchase program announced on October 31, 2013. Post the increase, Cardinal Health now has the authorization to repurchase up to approximately $1.7 billion of shares until December 31, 2016. In addition, the Board also announced some leadership changes. John F. Finn, a Cardinal Health Director since 1994, has decided not to go for re-election when his term expires at the 2014 annual meeting of shareholders. According to the Company, Mr. Finn, a Lead Director since 2009 and Chair of the Nominating and Governance Committee since 2012, will be replaced by Gregory B. Kenny, effective November 1, 2014. The full research reports on Cardinal Health are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/CAH/report.pdf

SolarCity Corporation Research Reports
On August 20, 2014, SolarCity Corporation (SolarCity) announced expansion of its Massachusetts operations with a new 10,000 square foot North Shore Operations Center in Wilmington. According to the Company, the new Operations center is SolarCity's third in Massachusetts and allows the Company to meet growing solar demand in the northeastern part of the state. The full research reports on SolarCity are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/SCTY/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review